Metabolic & Weight Management

Semaglutide

Also known as Ozempic · Wegovy · Rybelsus

Clinically studiedSubcutaneous injectionOralFDA-approved (Ozempic/Rybelsus for type 2 diabetes; Wegovy for weight management). Carries a boxed warning for thyroid C-cell tumor risk seen in rodents.

Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the incretin hormone GLP-1. It enhances glucose-dependent insulin secretion, slows gastric emptying, and acts on appetite-regulation centers in the brain to reduce food intake. It is marketed in injectable and oral formulations under different brand names for different approved uses.

Studied / used for

studied for glycemic control in type 2 diabetes
studied for chronic weight management in obesity/overweight
studied for reducing major adverse cardiovascular events

Commonly reported side effects

nausea
vomiting
diarrhea
constipation
abdominal pain
decreased appetite
fatigue

Clinically studied. Supported by human clinical trials. This reflects the strength of the research base, not effectiveness or a recommendation.

Not medical advice.

This is an educational reference. Peptalk does not recommend, prescribe, endorse, or rate any compound, and provides no dosing information. Do not start, stop, or change any peptide, hormone, supplement, or therapy based on this page. All clinical decisions must be made with your licensed healthcare provider.

← Back to all compounds